Jade Biosciences (JBIO) Stock Forecast: StockMap's 2-Week Call
JBIO stock forecast: StockMap's model leans Underperform on Jade Biosciences for the two weeks after the Nov 19 close, toward JBIO trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 4 of 6 two-week windows on JBIO since Aug 21; by chance, a call on the same dates was right 58% of the time.
Jade Biosciences last closed at $15.06, -2.78% on the session.
Against the IVW growth benchmark the position is -0.45% over the forecast window.
Jade Biosciences' market cap is $1.04B as of November 19, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -24 (too close to call).
Where JBIO sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 2 bullish and 13 bearish.
Agreement across those insights is 87%.
44 daily calls for JBIO so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Jade Biosciences in the 19th percentile on return on equity, where 100 is best.
Jade Biosciences is classified under Health Care / Biotechnology.
StockMap tracks Jade Biosciences as the 127th largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite Jade Biosciences ranks 189th of 394 in the group, against a group median of -0.27.